 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
- narmafotinib (AMP945) / Amplia Therap
Pulsed priming with narmafotinib enhances both gemcitabine/Abraxane & FOLFIRINOX response in pancreatic cancer (Poster and Exhibition Hall) - May 26, 2024 - Abstract #EACR2024EACR_772;
- narmafotinib (AMP945) / Amplia Therap
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel in first-line patients with advanced pancreatic cancer (ACCENT trial): Interim analysis. () - Apr 24, 2024 - Abstract #ASCO2024ASCO_6478;
P1/2
The trial will enrol up to 50 patients as part of the Phase 2 expansion cohort. Clinical trial information: NCT05355298.
- | narmafotinib (AMP945) / Amplia Therap
Phase classification, Combination therapy: ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer (clinicaltrials.gov) - Mar 6, 2024
P1/2, N=62, Recruiting, Sponsor: Amplia Therapeutics Limited
Clinical trial information: NCT05355298. Phase classification: P1b/2a --> P1/2
- narmafotinib (AMP945) / Amplia Therap
Phase 1b/2a of narmafotinib (AMP945) in combination with gemcitabine and nab-paclitaxel (Abraxane) standard of care as first-line therapy in patients with advanced pancreatic cancer (ACCENT trial): interim analysis (Section 49) - Mar 5, 2024 - Abstract #AACR2024AACR_6664;
Phase classification: P1b/2a --> P1/2 Abstract is embargoed at this time.
- AMP945 / Amplia Therap
The effect of adding a selective FAK inhibitor AMP945 to FOLFIRINOX in a model of pancreatic cancer. () - Apr 26, 2023 - Abstract #ASCO2023ASCO_4823;
P1b/2a
The FAK inhibitor AMP945, given in a pulsed-dosing regimen in combination with FOLFIRINOX, significantly enhances survival in a mouse model of pancreatic cancer by increasing apoptosis and reducing tumor burden, highlighting the potential of this combination in clinical treatment of PC. A clinical study of the combination of AMP945 with FOLFIRINOX is now in planning.
- AMP945 / Amplia Therap
A novel Focal Adhesion Kinase inhibitor AMP945 for first-line treatment of pancreatic cancer () - Jan 13, 2023 - Abstract #LCC2023LCC_155;
P1b/2a
Once daily oral dosing has anticipated benefits in terms of limitation of risk of acquired resistance, minimal potential for drug-drug interactions, adherence to therapy, and allows patients to self- administer AMP945 with the aim of potentiating response to standard of care chemotherapy. This presentation will describe the preclinical and clinical evidence gathered so-far that supports progression of AMP945 combination therapy in patients with advanced pancreatic cancer.
- | AMP945 / Amplia Therap
#AmpliaTherapeutics reported Dose Escalation Approved in #ACCENTClinicalTrial of #AMP945 $ATX https://t.co/pSMxni6Yr4 (Twitter) - Jan 11, 2023
- ||| narmafotinib (AMP945) / Amplia Therap
Enrollment open, Combination therapy: ACCENT: AMP945 in Combination With Nab-paclitaxel and Gemcitabine for Treatment of Pancreatic Cancer (clinicaltrials.gov) - Jul 7, 2022
P1b/2a, N=62, Recruiting, Sponsor: Amplia Therapeutics Limited
This presentation will describe the preclinical and clinical evidence gathered so-far that supports progression of AMP945 combination therapy in patients with advanced pancreatic cancer. Not yet recruiting --> Recruiting
- || AMP945 / Amplia Therap
FDA event: #AmpliaTherapeutics #AMP945 Pre-IND Meeting conducted $ATX https://t.co/bHGaACxlIC (Twitter) - May 10, 2022
- AMP945 / Amplia Therap
A phase 1 trial of AMP945, a potent and selective focal adhesion kinase inhibitor, in healthy volunteers (E-Poster Website) - Mar 9, 2022 - Abstract #AACR2022AACR_6691;
AMP945 PK and pharmacodynamic data demonstrate wide tissue distribution and target engagement. These data support continued development of AMP945 in patients with solid tumors and fibrotic diseases in which FAK inhibition could be beneficial.
- | AMP945 / Amplia Therap
#Amplia Completes Manufacture Of #AMP945 For Planned Trials $ATX https://t.co/B3HUdTrfI1 (Twitter) - Jan 14, 2022
- | AMP886 / Amplia Therap
#AMPLIA and #CRUK Agree to Amend Licence Terms for #AMP886 $ATX https://t.co/UpANSBdzoS (Twitter) - Nov 8, 2021
- | MIS416 / Amplia Therap
Journal: Innate Signaling in the CNS Prevents Demyelination in a Focal EAE Model. (Pubmed Central) - Jun 22, 2021
Moreover, intrathecal MIS416 altered the composition of early CNS infiltrates, increasing proportions of myeloid and NK cells and reducing T cells at the lesion site. This study contributes to an increased understanding of how innate immune responses can play a protective role, which in turn may lead to additional therapeutic strategies for the prevention and treatment of demyelinating pathologies.
- || AMP945 / Amplia Therap
#AmpilaTherapeutics reported #Amp945 Improves Survival In #PancreaticCancer Model $ATX https://t.co/ufMeowr62Y (Twitter) - Jun 3, 2021
- | MIS416 / Amplia Therap
Journal, IO biomarker: Innate signaling within the central nervous system recruits protective neutrophils. (Pubmed Central) - Dec 30, 2020
In contrast to intrathecal administration, intravenous administration of MIS416 led to monocyte but not neutrophil infiltration to the CNS. We thus identify a CNS-intrinsic and -specific phagocytosis-induced recruitment of anti-inflammatory neutrophils that contribute to CNS homeostasis and may have therapeutic potential.
- | MIS416 / Amplia Therap
Journal: TLR9-dependent interferon production prevents group 2 innate lymphoid cell-driven airway hyperreactivity. (Pubmed Central) - May 31, 2020
TLR9 activation alleviates ILC2-driven AHR and airway inflammation through direct suppression of cell function. Microparticle-based delivery of TLR9 ligands may serve as a therapeutic strategy for asthma treatment.
- || MIS416 / Innate
Clinical, P1 data, Clinical Trial,Phase I, Journal: First-in-human phase I clinical trial of the NY-ESO-1 protein cancer vaccine with NOD2 and TLR9 stimulants in patients with NY-ESO-1-expressing refractory solid tumors. (Pubmed Central) - Apr 21, 2020
In a preclinical study, adding anti-PD-1 monoclonal antibody to CHP-NY-ESO-1 and MIS416 induced significant tumor suppression. This combination therapy is a promising next step.
- MIS416 / Innate
Differential monocytic response patterns to MIS416 in vitro during progressive multiple sclerosis and the involvement of NF-kB. (Poster Exhibition) - Aug 28, 2019 - Abstract #ECTRIMS2019ECTRIMS_1593;
These findings support a central role for NF-kB pathway mutations in regulating monocyte responses to MIS416. Overall, this work indicates that MIS416 therapy has the potential to modulate peripheral immune responses through substantive TF and cytokine induction, which can alter the immune milieu following in vivo treatment.
- | MIS416 / Amplia Therap
Enrollment change, Trial withdrawal: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 1, 2018
P1, N=0, Withdrawn, Sponsor: Roswell Park Cancer Institute
Overall, this work indicates that MIS416 therapy has the potential to modulate peripheral immune responses through substantive TF and cytokine induction, which can alter the immune milieu following in vivo treatment. N=12 --> 0 | Recruiting --> Withdrawn
- | MIS416 / Amplia Therap
Enrollment open: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Dec 28, 2017
P1, N=12, Recruiting, Sponsor: Roswell Park Cancer Institute
N=12 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- |||| MIS416 / Amplia Therap
Trial completion: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jul 17, 2017
P2b, N=93, Completed, Sponsor: Innate Immunotherapeutics
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | MIS416 / Amplia Therap
Trial primary completion date: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jun 2, 2017
P1, N=12, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
Active, not recruiting --> Completed Trial primary completion date: Aug 2017 --> Aug 2018
- MIS416 / Amplia Therap
New P1 trial: Sirolimus and Vaccine Therapy in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - Jul 14, 2016
P1, N=12, Not yet recruiting, Sponsor: Roswell Park Cancer Institute
- ||| MIS416 / Amplia Therap
Enrollment closed, Trial primary completion date: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Apr 26, 2016
P2b, N=93, Active, not recruiting, Sponsor: Innate Immunotherapeutics
Trial primary completion date: Aug 2017 --> Aug 2018 Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017
- AMP886 / Amplia Therap
Enrollment change, HEOR: Health Status and Quality of Life in the Elderly (clinicaltrials.gov) - Mar 11, 2015
P=N/A, N=12, Terminated, Sponsor: Unilever R&D
Recruiting --> Active, not recruiting | Trial primary completion date: May 2016 --> Mar 2017 N=84 --> 12
- MIS416 / Amplia Therap
Trial primary completion date: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Jan 18, 2015
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
N=84 --> 12 Trial primary completion date: Dec 2015 --> May 2016
- AMP886 / Amplia Therap
Trial termination, HEOR: Health Status and Quality of Life in the Elderly (clinicaltrials.gov) - Sep 4, 2014
P=N/A, N=84, Terminated, Sponsor: Unilever R&D
Trial primary completion date: Dec 2015 --> May 2016 Recruiting --> Terminated; Recruitment problems
- | MIS416 / Amplia Therap
New P2b trial: Safety and Efficacy Study of MIS416 to Treat Secondary Progressive Multiple Sclerosis (clinicaltrials.gov) - Aug 29, 2014
P2b, N=90, Recruiting, Sponsor: Innate Immunotherapeutics
- ||| AMP886 / Amplia Therap
Enrollment open, HEOR: Health Status and Quality of Life in the Elderly (clinicaltrials.gov) - Oct 16, 2013
P=N/A, N=84, Recruiting, Sponsor: Unilever R&D
Recruiting --> Terminated; Recruitment problems Not yet recruiting --> Recruiting
- | MIS416 / Amplia Therap
Enrollment change, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
Not yet recruiting --> Recruiting N=24 --> 34
- | MIS416 / Amplia Therap
Trial completion, Immunomodulating: Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple Sclerosis (clinicaltrials.gov) - Dec 4, 2012
P1/2, N=34, Completed, Sponsor: Innate Therapeutics Limited
N=24 --> 34 Active, not recruiting --> Completed